Melatonin and Autoimmune Diseases: Safety, Interactions, and Clinical Guidance

Melatonin, an endogenous hormone regulating circadian rhythm, is widely used as a sleep supplement. Its use in autoimmune diseases requires nuanced consideration.

General Safety

• Short-term use (≤3 months) is well-tolerated at 0.5–5 mg.
• Common side effects: headache, dizziness, nausea, daytime drowsiness.
• No absolute contraindication for autoimmune diseases per major rheumatology guidelines.

Theoretical Concerns

• Immune modulation: Melatonin enhances Th1 responses, NK cell activity, and cytokine production (IL-2, IL-6, IFN-γ). In Th1-driven diseases (RA, MS, type 1 DM), this could theoretically exacerbate inflammation.
• Animal models: Some lupus-prone mice show worsened disease with melatonin; others show benefit. Human data are limited.
• Clinical reports: Rare case reports of flare with melatonin in SLE, RA; many patients use without issue.

Practical Recommendations

• Discuss with rheumatologist/immunologist before starting.
• Start low (0.3–1 mg), monitor for flare (joint pain, rash, fatigue, labs).
• Avoid in active, uncontrolled disease or with potent immunosuppressants (uncertain interaction).
• Prefer non-pharmacologic sleep hygiene first (CBT-I, light exposure, schedule regularity).
• If used, choose USP-verified product; avoid "time-release" if middle insomnia (may cause morning grogginess).

Special Populations

• Pregnancy/breastfeeding: Insufficient safety data—avoid.
• Children: Only under specialist guidance.
• On anticoagulants: Theoretical bleeding risk (melatonin may affect platelet aggregation).

Evidence is evolving; individualized decision-making is key.